Skip to main content

Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

The Original Article was published on 06 November 2013

Retraction Note: BMC Cancer 13, 527 (2013)

The Editor has retracted this article because it appears that some of the text and figures have been previously published by some of the same authors. Specifically:

  • there is substantial text overlap with results section in [1]

  • Figure 2B appears to present the same data as Fig. 1C in [1]

  • It appears the same FACS plots have been presented in Fig. 3B (for srfn, poly (I:C) and control) as in Fig. 4A in [1]

  • Figure 3C (sifn and Poly(I:C) ) and 3D appear to show the same images as those published previously in [1] in Fig. 3A

Author Yu-Yin Xu does not agree to this retraction. None of the other authors have responded to any correspondence from the editor or publisher about this retraction


  1. Chen, L., Xu, Y., Zhou, J., Wu, Y., E, Q., Zhu, Y. “TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells”. Oncology Reports 28.1 (2012): 200–206.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Li Chen.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, YY., Chen, L., Wang, GL. et al. Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. BMC Cancer 23, 636 (2023).

Download citation

  • Published:

  • DOI: